Literature DB >> 16034481

The corticotropin-releasing factor-hypocretin connection: implications in stress response and addiction.

C Pañeda1, R Winsky-Sommerer, B Boutrel, L de Lecea.   

Abstract

The hypothalamic neuropeptides hypocretins (orexins) play a crucial role in the stability of arousal and alertness. Recent data have raised the hypothesis that hypocretin neurons are also part of the circuitries that mediate the hypothalamic stress response. In particular, we have recently demonstrated that corticotrophin-releasing factor (CRF)-immunoreactive terminals make direct synaptic contacts with hypocretin-expressing neurons and that numerous hypocretinergic neurons express the CRF-R1/2 receptors. Furthermore, CRF excites hypocretinergic cells ex vivo through CRF-R1 receptors. Activation of hypocretinergic neurons in response to acute stress is severely impaired in CRF-R1 knockout mice. Moreover, the stress response is impaired in hypocretin-deficient mice. We propose that upon stressor stimuli, CRF stimulates the release of hypocretins, and this circuit contributes to activation and maintenance of arousal associated with the stress response and addiction. 2005 Prous Science. All rights reserved

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16034481     DOI: 10.1358/dnp.2005.18.4.908659

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  14 in total

1.  Nicotine self-administration in the rat: effects of hypocretin antagonists and changes in hypocretin mRNA.

Authors:  Mark G LeSage; Jennifer L Perry; Catherine M Kotz; David Shelley; William A Corrigall
Journal:  Psychopharmacology (Berl)       Date:  2010-02-24       Impact factor: 4.530

2.  The orexin system regulates alcohol-seeking in rats.

Authors:  Andrew J Lawrence; Michael S Cowen; Hong-Ju Yang; Feng Chen; Brian Oldfield
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

Review 3.  Tobacco dependence, the insular cortex and the hypocretin connection.

Authors:  Paul J Kenny
Journal:  Pharmacol Biochem Behav       Date:  2010-09-09       Impact factor: 3.533

Review 4.  Role of innate and drug-induced dysregulation of brain stress and arousal systems in addiction: Focus on corticotropin-releasing factor, nociceptin/orphanin FQ, and orexin/hypocretin.

Authors:  Rémi Martin-Fardon; Eric P Zorrilla; Roberto Ciccocioppo; Friedbert Weiss
Journal:  Brain Res       Date:  2009-12-21       Impact factor: 3.252

5.  Bmal1 knockdown suppresses wake and increases immobility without altering orexin A, corticotrophin-releasing hormone, or glutamate decarboxylase.

Authors:  Afaf Akladious; Sausan Azzam; Yufen Hu; Pingfu Feng
Journal:  CNS Neurosci Ther       Date:  2018-02-14       Impact factor: 5.243

6.  Hypocretin-1 dose-dependently modulates maternal behaviour in mice.

Authors:  K L D'Anna; S C Gammie
Journal:  J Neuroendocrinol       Date:  2006-08       Impact factor: 3.627

7.  Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy.

Authors:  Rong-Jian Liu; George K Aghajanian
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-02       Impact factor: 11.205

8.  Neuropeptide S reinstates cocaine-seeking behavior and increases locomotor activity through corticotropin-releasing factor receptor 1 in mice.

Authors:  Covadonga Pañeda; Salvador Huitron-Resendiz; Laura M Frago; Julie A Chowen; Roberto Picetti; Luis de Lecea; Amanda J Roberts
Journal:  J Neurosci       Date:  2009-04-01       Impact factor: 6.167

Review 9.  Hypocretin mechanisms in nicotine addiction: evidence and speculation.

Authors:  William A Corrigall
Journal:  Psychopharmacology (Berl)       Date:  2009-06-16       Impact factor: 4.530

10.  Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats.

Authors:  Jemma K Richards; Jeffrey A Simms; Pia Steensland; Sharif A Taha; Stephanie L Borgland; Antonello Bonci; Selena E Bartlett
Journal:  Psychopharmacology (Berl)       Date:  2008-05-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.